Vertex submits NDA for CF drug, MacroGenics reports ADC prostate cancer trial patient deaths, FTC extends review of Novo-Catalent deal [The good, the bad, the ugly]

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: 

The good —  Vertex submits NDA for CF drug
The bad — MacroGenics reports patient deaths in prostate cancer ADC trial 
The ugly — FTC extends review of Novo-Catalent deal